An Open-label, Multicenter, Phase 1b Study of CNTO 888 (an Anti-CCL 2 Monoclonal Antibody) in Combination With Chemotherapies for the Treatment of Subjects With Solid Tumors.

Trial Profile

An Open-label, Multicenter, Phase 1b Study of CNTO 888 (an Anti-CCL 2 Monoclonal Antibody) in Combination With Chemotherapies for the Treatment of Subjects With Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jun 2014

At a glance

  • Drugs Carlumab (Primary) ; Carboplatin; Docetaxel; Doxorubicin liposomal; Gemcitabine; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Centocor
  • Most Recent Events

    • 27 Feb 2012 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
    • 27 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top